ZEBETA Drug Patent Profile

When do Zebeta patents expire, and what generic alternatives are available?

Zebeta is a drug marketed by Teva Branded Pharm and is included in one NDA.

The generic ingredient in ZEBETA is bisoprolol fumarate. There are twelve drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the bisoprolol fumarate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zebeta

A generic version of ZEBETA was approved as bisoprolol fumarate by RUBICON RESEARCH on November 16^th, 2000.

Summary for ZEBETA

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ZEBETA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Branded Pharm	ZEBETA	bisoprolol fumarate	TABLET;ORAL	019982-002	Jul 31, 1992		DISCN	Yes	No
Teva Branded Pharm	ZEBETA	bisoprolol fumarate	TABLET;ORAL	019982-001	Jul 31, 1992		DISCN	Yes	No

International Patents for ZEBETA

See the table below for patents covering ZEBETA around the world.

Country	Patent Number	Title	Estimated Expiration
France	2367053
South Africa	7706018
United Kingdom	1532380
Australia	520307
Hungary	177868	PROCESS FOR PREPARING PHENOXY-AMINO-PROPANOLS
Sweden	441827	FORFARANDE FOR FRAMSTELLNING AV FENOXIAMINOPROPANOLER
Netherlands	7711042

ZEBETA Market Analysis and Financial Projection

Last updated: February 3, 2026

What Is ZEBETA and Why Is It Relevant for Investment?

ZEBETA (brand name for nebivolol) is a selective beta-1 adrenergic receptor blocker used primarily for hypertension and heart failure management. It holds a niche in cardio-metabolic therapy, with unique vasodilatory properties owing to nitric oxide release. Its market positioning is mid-tier, with moderate competition and established efficacy, especially among patients with comorbidities like diabetes.

What Are the Current Market Dynamics for ZEBETA?

ZEBETA has been on the market since 2007, primarily in Europe and select Asian markets. Its patent expired in many regions between 2014 and 2017, opening opportunities for generic manufacturers. The global antihypertensive drugs market was valued at approximately $55 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 3.8% through 2030.

While ZEBETA faces competition from other beta-blockers such as atenolol, bisoprolol, and metoprolol, its unique vasodilation effect (via nitric oxide pathways) differentiates it slightly. In markets like Japan, nebivolol accounts for about 15-20% of beta-blocker prescriptions for hypertension.

What Are the Key Patents and Regulatory Status?

Nebivolol was originally patented by Menarini in 1998, with market exclusivity lasting until approximately 2014. Generic competition began around that time, reducing profitability margins.

The United States FDA approved nebivolol under the NDA in 2007, with its patent expiring in 2017. The European Medicines Agency (EMA) approved it in 2007, with similar patent timelines. Patent expiry has led to a proliferation of generic versions, decreasing per-unit revenue for originator companies.

Market approvals for ZEBETA are maintained in regions like Europe, Asia-Pacific, and South America but are absent from the U.S. market unless alternative formulations are developed.

What Are the Investment Fundamentals for ZEBETA?

Market Size and Growth Potential

• The global antihypertensive market is growing steadily, driven by aging populations in North America, Europe, and Asia-Pacific.
• ZEBETA's share is limited due to generic competition, but its niche benefits—especially in patients with concomitant diabetic conditions—may sustain steady prescriptions.

Patent and Competition Outlook

• Patent expiration in major markets diminished exclusive revenue streams.
• Generics dominate pricing, reducing profit margins for the original manufacturer.
• Potential for reformulation, combination therapies, or biosimilars exists but is limited by existing patent landscapes.

R&D and Pipeline Developments

• No significant new formulations or indications are in late-stage development.
• Companies focusing on ZEBETA are diversifying into newer beta-blockers or competing therapies for hypertension.

Regulatory and Pricing Environment

• Pricing pressure is high worldwide, especially with increased focus on cost-effective treatments.
• Reimbursement policies favor generics, further compressing margins.

Financial Performance and Future Outlook

• Originator companies like Menarini saw a decline in nebivolol revenue post-2017 patent expiry.
• Investment in brand stewardship or lifecycle management strategies appears limited for ZEBETA.
• Market trends favor newer, branded alternatives with added benefits or fixed-dose combinations.

What Are the Risks and Opportunities?

Risks

• Continued erosion of market share due to generics.
• Market saturation with existing beta-blockers.
• Regulatory restrictions on pricing.
• Limited pipeline or formulation innovations.

Opportunities

• Developing fixed-dose combination drugs in hypertension.
• Expanding into emerging markets with expanding healthcare access.
• Potential repositioning for new indications (e.g., hypertensive patients with specific comorbidities).

Key Takeaways

• ZEBETA’s original patent expired in 2017, leading to intense generic competition.
• Market growth is driven by demographic shifts but is limited by pricing pressures and existing competition.
• No significant new formulations or indications are currently under development.
• Investment in ZEBETA alone offers limited upside without differentiation or lifecycle extensions.
• The primary value lies in niche markets and emerging regions with less generic penetration.

FAQs

1. Can ZEBETA regain market share through new indications?
Unlikely, as no late-stage development for additional indications is currently reported.

2. How does the market for nebivolol compare globally?
It remains more significant in Europe and Asia-Pacific; the U.S. market is limited since FDA approvals for newer formulations are absent.

3. Are biosimilars or generics expected to dominate the market?
Yes, generics already dominate, with price competition expected to suppress margins further.

4. Could combination formulations revitalize ZEBETA’s market?
Potentially, but such formulations face regulatory and patent hurdles, and no such products are in advanced development.

5. What strategic moves could benefit investments in nebivolol?
Targeting emerging markets, integrating with combination therapies, or developing innovative formulations could offer opportunities, though these are uncertain and require significant R&D investment.

---

Sources:
[1] GlobalData, "Pharmaceuticals Market Analysis," 2022.
[2] European Medicines Agency, "Nebivolol Summary," 2007.
[3] U.S. FDA NDA approval documentation, 2007.
[4] MarketWatch, "Antihypertensive Drugs Market Forecast," 2023.
[5] Menarini Group annual report, 2022.